PAMP (Proadrenomedullin N-terminal 20 Peptide)
The 20-amino-acid partner of adrenomedullin — a blood-pressure-lowering peptide that puts a brake on adrenaline release. A research peptide, not a drug
PAMP — proadrenomedullin N-terminal 20 peptide — is a 20-amino-acid peptide cut from the front end of the same precursor protein that makes adrenomedullin. The two are 'gene-related partners': one gene, preproadrenomedullin, yields both. Like adrenomedullin, PAMP lowers blood pressure, but its signature action is different — it is a brake on the sympathetic 'fight-or-flight' output of the adrenal gland. PAMP is stored in, and released from, the adrenaline-making chromaffin cells alongside adrenomedullin and the catecholamines themselves, and once released it blocks the nicotinic receptors that drive catecholamine secretion, damping the response. Beyond this, research has given PAMP a varied portfolio: injected into the brain of animals it raises blood glucose (through the bombesin/GRP receptor) and curbs food intake and stomach emptying (through a receptor of its own); it slows the growth of tumour cells; it sits in the renin-storing cells of the kidney; and it even kills bacteria, behaving like a natural antimicrobial peptide. A shorter active fragment, PAMP-12, shares many of these effects. PAMP is studied as a research peptide; it is not an approved medicine and has not been given to people as a treatment. (It should not be confused with the unrelated immunology term 'PAMP', pathogen-associated molecular pattern.)
No established human dose Details ↓
Recommended Dosing
No established human dose
PAMP is an endogenous peptide that has never been given to people as a treatment. The work is in animals and cells, where PAMP is given into the brain or applied to cells at experimental amounts that do not carry over to people.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Adrenomedullin is a well-known blood-pressure-lowering peptide, and when the body makes it, it makes something else at the same time. The precursor protein, preproadrenomedullin, is cut into two active peptides: adrenomedullin itself and, from the front (N-terminal) end, a 20-amino-acid peptide named PAMP — proadrenomedullin N-terminal 20 peptide. Because they come from one gene, PAMP and adrenomedullin are described as gene-related partners, and both lower blood pressure, though by different routes.
PAMP's most distinctive role is as a brake on the sympathetic nervous system. In the adrenal medulla it is stored in the chromaffin cells — the cells that release adrenaline and noradrenaline — and is co-secreted with those catecholamines and with adrenomedullin whenever the cells are stimulated. Once out, PAMP acts back on the same cells as an 'anticholinergic' or antinicotinic peptide: it blocks the nicotinic receptors and the sodium and calcium currents that normally trigger catecholamine release, so it dampens the adrenaline surge. This self-limiting loop is one of the clearest examples of a co-released peptide tuning its own gland.
PAMP also has a set of central, metabolic actions. Injected into the brain of fasted mice it raises blood glucose — an effect it produces through the bombesin / gastrin-releasing-peptide receptor, with which it shares a few key residues, and through alpha-adrenergic release of glucagon. Through a separate, PAMP-specific receptor it also inhibits food intake and slows gastric emptying. These overlapping but mechanistically distinct effects mark PAMP as a multifunctional regulatory peptide rather than a one-target hormone.
The reach extends further. PAMP inhibits the proliferation of human neuroblastoma cells by shutting down N-type calcium channels through a pertussis-toxin-sensitive G protein — a pathway different from adrenomedullin's. It is found in the renin-storing juxtaglomerular cells of the kidney, linking it to blood-pressure control at the level of the renin system. And, being rich in basic and hydrophobic amino acids like many antimicrobial peptides, PAMP (and its fragment PAMP-12) can kill bacteria by entering the cell and binding their DNA. Mice engineered to lose PAMP while keeping adrenomedullin survive to adulthood and are fertile, a tool that is helping separate the two peptides' jobs.
PAMP is an endogenous research peptide. No published study has given PAMP to people as a treatment — the work is in animals and cells — it is approved nowhere, and material sold online as 'PAMP' is an unregulated research chemical. Nothing here is a dose or a therapy; this page records what the published science says about the peptide.
Mechanism of Action
PAMP is a 20-residue peptide cut from the N-terminal region of the adrenomedullin precursor. Like adrenomedullin it is hypotensive, but its signature action is sympatho-inhibitory: co-released with adrenomedullin and catecholamines from chromaffin cells, it blocks nicotinic-receptor-driven catecholamine secretion. It also has central metabolic actions and an antiproliferative, antimicrobial profile.
Adrenomedullin-precursor processing
PAMP is processed from the N-terminal region of preproadrenomedullin, the same precursor as adrenomedullin, and is co-stored and co-secreted with it and the catecholamines from chromaffin cells (PMIDs 7798947, 30537525).
Sympatho-inhibition (anticholinergic)
PAMP blocks nicotinic-receptor sodium and calcium currents in adrenal medullary cells, damping catecholamine release as a self-limiting brake on the sympathoadrenal system (PMID 7798947).
Central metabolic + other actions
Central PAMP raises blood glucose via the bombesin/GRP receptor (PMID 10812076) and inhibits food intake and gastric emptying via a selective PAMP receptor (PMID 11311728); it also inhibits tumour-cell growth via N-type Ca channels (PMID 9303556).
Published Research
These are studies of PAMP read from their PubMed abstracts on November 6, 2026. They include a review of its novel actions, a study of its anticholinergic inhibition of catecholamine release in adrenal cells, animal studies of its effects on blood glucose and on food intake and gastric emptying, a study of its anti-proliferative action on human neuroblastoma cells, and a PAMP-knockout mouse model. PAMP has not been given to people as a treatment; the evidence is animal and cell work.
Novel actions of PAMP
A review of newly identified actions of PAMP, a hypotensive peptide from the adrenomedullin precursor. Beyond its cardiovascular effects, central PAMP raised blood glucose (via the bombesin receptor, blocked by a bombesin antagonist) and inhibited food intake and gastric emptying in fasted mice, and the review also notes effects on body temperature and oxygen consumption — framing PAMP as a multifunctional regulatory peptide (a review).
PAMP is an anticholinergic brake on catecholamine release
In cultured bovine adrenal medullary cells, PAMP was co-secreted with catecholamines by calcium-dependent exocytosis when nicotinic receptors were stimulated, in a fixed molar ratio. Added back, PAMP(1-20) blocked the nicotinic-receptor sodium influx, the downstream calcium influx and catecholamine secretion in a non-competitive manner, without affecting potassium- or veratridine-evoked responses — identifying PAMP as a novel antinicotinic peptide that brakes its own gland (a cell study).
PAMP raises blood glucose via the bombesin receptor
Given into the brain of fasted mice, PAMP produced a potent rise in blood glucose. PAMP shares four residues with bombesin and bound the gastrin-releasing-peptide and neuromedin-B receptors; the hyperglycaemia was blocked by a GRP-receptor antagonist and by alpha-adrenergic blockade, indicating it acts at least in part through the bombesin/GRP receptor and glucagon release (a preclinical result).
PAMP inhibits food intake and gastric emptying
Centrally administered PAMP dose-dependently decreased food intake and delayed gastric emptying in fasted mice. Unlike its hyperglycaemic effect, these actions were NOT blocked by a bombesin antagonist and persisted in mice lacking the gastrin-releasing-peptide receptor or bombesin receptor subtype-3 — indicating they are mediated by a separate, PAMP-specific receptor (a preclinical result).
PAMP inhibits neuroblastoma-cell growth
Both PAMP and adrenomedullin inhibited growth and DNA synthesis in human neuroblastoma TGW cells, but by different mechanisms: a CGRP antagonist and an adrenomedullin antagonist reversed adrenomedullin's effect but not PAMP's, whereas pertussis toxin and an N-type calcium-channel blocker abolished PAMP's effect — showing PAMP acts through N-type calcium channels and pertussis-toxin-sensitive G-protein-coupled receptors (a cell study).
PAMP-knockout mice are viable
Mice engineered to delete the PAMP coding sequence while preserving adrenomedullin survived to adulthood and were fertile (females had small litters). They expressed somewhat lower adrenomedullin messenger RNA and peptide, yet with a normal spatiotemporal pattern in the heart — providing a publicly available model to study PAMP's function independently of adrenomedullin (a preclinical result).
No Established Human Dose
PAMP is an endogenous peptide that has never been given to people as a treatment. The work is in animals and cells, where PAMP is given into the brain or applied to cells at experimental amounts that do not carry over to people. No regulator has approved any dose, and no published human dose exists, so no amount is printed here.
What this rests on: PMID 11754967, PMID 7798947, PMID 11311728.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes PAMP (Proadrenomedullin N-terminal 20 Peptide) is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
Unknown: no human dose of PAMP (Proadrenomedullin N-terminal 20 Peptide) has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store PAMP (Proadrenomedullin N-terminal 20 Peptide), before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long PAMP (Proadrenomedullin N-terminal 20 Peptide) stays intact once mixed.
How it is taken
Unknown: with no established human dose, there is no established way of taking PAMP (Proadrenomedullin N-terminal 20 Peptide). What the human studies gave and how is set out under No Established Human Dose.
What to expect, and when
How long it stays in the body: a half-life of not established for humans as a drug; an endogenous precursor peptide. After about five half-lives almost none is left.
When effects appear: unknown; no source on this page gives a time to effect for PAMP (Proadrenomedullin N-terminal 20 Peptide). Results reported in the studies are under Published Research.
Source: half-life: PMID 11754967.
Side effects, and when to stop or get help
From the Side Effects section: No human adverse-event data exist: no published study has administered PAMP to people; In animals it lowers blood pressure, brakes adrenaline release and alters blood glucose, food intake and gastric emptying (PMIDs 7798947, 10812076, 11311728) — preclinical signals, not a human safety profile; It shares a precursor and some actions with adrenomedullin but works through distinct receptors (PMID 9303556); Material sold online as 'PAMP' is an unregulated research chemical of unverified content. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping PAMP (Proadrenomedullin N-terminal 20 Peptide). Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“PAMP is a research peptide that has not been given to people as a drug, so there is no human safety profile; the points below reflect that research status”).
Interactions
Unknown: a PubMed search for human interaction studies of PAMP (Proadrenomedullin N-terminal 20 Peptide) (reviewed 2026-11-06) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of PAMP (Proadrenomedullin N-terminal 20 Peptide) products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Research Chemical (Not a drug: Drugs@FDA and the openFDA label endpoint hold no record, and FDA GSRS and ChEMBL hold no substance record for PAMP (searched November 6, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
PAMP is a research peptide that has not been given to people as a drug, so there is no human safety profile; the points below reflect that research status.
Contraindications & Cautions
PAMP has no approved use and no label. These points reflect its research status.
Legal Status
PAMP (proadrenomedullin N-terminal 20 peptide) is an endogenous peptide studied as a research compound; it is not a drug and is not approved in any country.
Frequently Asked Questions
?What is PAMP?
PAMP (proadrenomedullin N-terminal 20 peptide) is a 20-amino-acid peptide cut from the front of the adrenomedullin precursor — so it is made by the same gene as adrenomedullin and the two are released together.
?What does it do?
Like adrenomedullin it lowers blood pressure, but its signature role is braking adrenaline release: it blocks the nicotinic receptors that trigger catecholamine secretion in the adrenal gland (PMID 7798947). It also raises blood glucose and curbs food intake centrally (PMIDs 10812076, 11311728).
?Is this the same as the immunology term PAMP?
No. In immunology 'PAMP' means pathogen-associated molecular pattern, a completely different concept. Here PAMP is a peptide hormone, proadrenomedullin N-terminal 20 peptide; the shared abbreviation is a coincidence.
?Is it approved or available to buy?
No. PAMP is not a medicine, has no FDA application or label, and is approved nowhere. Material sold online as PAMP is an unregulated research chemical. Grey Peptides lists no sellers and recommends no source; this page records the published science.
References
- [review] Ohinata K, et al. "Novel actions of proadrenomedullin N-terminal 20 peptide (PAMP)." Peptides, 2001;22(11):1809-16. PMID: 11754967.
- [mechanism] Katoh F, et al. "Proadrenomedullin N-terminal 20 peptide (PAMP), an endogenous anticholinergic peptide: its exocytotic secretion and inhibition of catecholamine secretion in adrenal medulla." J Neurochem, 1995;64(1):459-61. PMID: 7798947.
- [animal] Ohinata K, et al. "Proadrenomedullin N-terminal 20 peptide (PAMP) elevates blood glucose levels via bombesin receptor in mice." FEBS Lett, 2000;473(2):207-11. PMID: 10812076.
- [animal] Ohinata K, et al. "Proadrenomedullin N-terminal 20 peptide (PAMP) inhibits food intake and gastric emptying in mice." Peptides, 2001;22(4):589-95. PMID: 11311728.
- [mechanism] Ando K, et al. "Proadrenomedullin N-terminal 20 peptide (PAMP) inhibits proliferation of human neuroblastoma TGW cells." FEBS Lett, 1997;413(3):462-6. PMID: 9303556.
- [animal] Matson BC, et al. "Genetic loss of proadrenomedullin N-terminal 20 peptide (PAMP) in mice is compatible with survival." Peptides, 2019;112:96-100. PMID: 30537525.
- [other] UniProt P35318 (ADM / pro-adrenomedullin, ADM gene), read November 6, 2026: proadrenomedullin N-terminal 20 peptide (PAMP) is a 20-residue peptide processed from the N-terminal region of preproadrenomedullin, the same precursor that yields adrenomedullin; a shorter form, PAMP-12 (residues 9-20), is also produced. https://www.uniprot.org/uniprotkb/P35318/entry
- [other] PAMP was identified as the N-terminal peptide of the adrenomedullin precursor and named proadrenomedullin N-terminal 20 peptide; its hypotensive and sympatho-inhibitory (anticholinergic) actions, its co-secretion with adrenomedullin and catecholamines, and its central metabolic effects are from the studies carded on this page (read November 6, 2026). Not to be confused with the immunology term 'PAMP' (pathogen-associated molecular pattern).
- [other] US FDA, Drugs@FDA and the drug label endpoint (openFDA), searched November 6, 2026: no application and no label record for proadrenomedullin N-terminal 20 peptide (PAMP). It is an endogenous peptide, not a registered drug; FDA GSRS and ChEMBL hold no substance record for it.
Sources & Citations
The six studies carded above were read from their PubMed records on November 6, 2026. Identity comes from UniProt (P35318, pro-adrenomedullin): PAMP is the N-terminal 20-residue peptide of the adrenomedullin precursor. Its hypotensive and sympatho-inhibitory (anticholinergic) actions, its co-secretion with adrenomedullin and catecholamines, its central effects on glucose, food intake and gastric emptying, its antiproliferative action and the PAMP-knockout model are from the studies carded on this page; the absence of US approval and of a drug substance record from Drugs@FDA, openFDA, FDA GSRS and ChEMBL was checked the same day. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.